Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer

Sato, Motohiro; Okumura, Toshiyuki; Kaito, Keiko; Kiyoshima, Moriyuki; Asato, Yuji; Uchiumi, Keiko; Iijima, Hiroaki; Hashimoto, Ikuta; Kaburagi, Takayuki; Amemiya, Ryuta

doi:10.1007/s12149-008-0205-5

Cited by 21 publications

(17 citation statements)

References 18 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Imaging studies may aid with the differential diagnosis between lung cancer and pancreatic cancer in patients with a pancreatic mass and a history of malignant lung neoplasm (14)(15)(16). A history of lung cancer may lead to the diagnosis of pancreatic metastasis.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review

et al. 2015

View full text Add to dashboard Cite

Abstract. The current study presents two cases of gastrointestinal (GI) bleeding due to pancreatic metastasis of non-small cell lung cancer (NSCLC). The two patients had a history of lung adenocarcinoma prior to pancreatic metastasis. The first patient presented with melena, epigastric pain and weight loss, and the second patient presented with melena and weight loss. The diagnoses were confirmed by biopsy of the metastatic lesions. Immunohistochemistry is useful for managing the differential diagnosis between lung cancer and pancreatic carcinoma in patients with a history of lung cancer. Chemotherapy prolonged the survival of the second patient. However, the first patient received no chemotherapy and succumbed to NSCLC six weeks after the diagnosis of metastatic pancreatic cancer. GI bleeding as a result of pancreatic metastasis of NSCLC is extremely rare; including the present two cases, only three cases have been reported in the English literature. The current study is presented in order to increase the awareness of GI hemorrhage as a manifestation of this relatively rare condition.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Although the most common cancer metastasizing to pancreas is lung cancer [16], we can very rarely encounter such patients in clinical practice. Because the pancreatic mass in our patient showed very different histology compared to primary lung cancer and there were no other aggravating lesions during erlotinib, we initially suspected that it would be primarily originated from pancreas.…”

Section: Discussionmentioning

confidence: 99%

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

et al. 2011

View full text Add to dashboard Cite

“…F-18-FDG-PET/CT was performed using a PET/CT scanner (Biograph 16 LSO Hi-Rez; Siemens Japan K.K., Tokyo, Japan) with previously mentioned configurations [19,20] . All patients fasted for 6 h before receiving an intravenous injection of 220-300 MBq F-18-FDG (Nihon Mediphysics Co., Tokyo, Japan).…”

Section: F-18-fdg-pet/ct and Contrast-enhanced Ct Scanningmentioning

confidence: 99%

“…with the fusion of PET images and ceCT images. These images were interpreted by 2 experienced physicians who were not blinded to clinical information [20] ( fig. 1 ).…”

Section: F-18-fdg-pet/ct Image and Cect Interpretationmentioning

confidence: 99%

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

Sasaki

Kawasaki²,

Sato³

et al. 2016

Dig Surg

Self Cite

View full text Add to dashboard Cite

Background/Aims: Although the diagnostic value of fluorine-18 2-fluoro-2-deoxy-D-glucose (F-18-FDG) positron emission tomography/computed tomography (F-18-FDG-PET/CT) in patients with colorectal cancer (CRC) has been reported, the association between the F-18-FDG uptake in metastatic lymph nodes (FDG_LN) and clinicopathological variables has not been fully investigated. We evaluated the diagnostic value of F-18-FDG-PET/CT in detecting LN metastasis from CRC, and the relationship between F-18-FDG-PET/CT-detecting LN metastasis and prognosis. Methods: We retrospectively analyzed the medical records of 370 patients who underwent preoperative F-18-FDG-PET/CT, followed by surgical resection for CRC between January 2007 and December 2010. We analyzed the sensitivity, specificity, and accuracy of F-18-FDG-PET/CT and CT in diagnosing metastatic LNs. Survival was analyzed in 115 patients with stage III CRC. Results: The sensitivity, specificity, and accuracy for detecting metastatic LNs using F-18-FDG-PET/CT were 56.8, 90.3, and 74.2%, and those for contrast-enhanced CT were 38.4, 95.5, and 65.0%, respectively. The accuracy of F-18-FDG-PET/CT was significantly associated with tumor depth and lymphatic involvement. In the survival analysis, cancer-specific survival and the disease-free survival were significantly shorter in patients with stage III CRC with FDG_LN than in those without FDG_LN. Conclusion: F-18-FDG-PET/CT had low sensitivity and high specificity for detecting metastatic LNs from CRC. FDG_LN independently predicted poor prognosis in patients with stage III CRC.

show abstract

Usefulness of FDG-PET/CT in the detection of pancreatic metastases from lung cancer

Cited by 21 publications

References 18 publications

Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review

Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

Impact of Fluorine-18 2-Fluoro-2-Deoxy-<smlcap>D</smlcap>-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer

Contact Info

Product

Resources

About